Locomotor Training with Anabolic Adjuvants for Musculoskeletal Recovery After SCI

使用合成代谢佐剂进行运动训练以促进 SCI 后的肌肉骨骼恢复

基本信息

  • 批准号:
    9505304
  • 负责人:
  • 金额:
    --
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-07-01 至 2022-06-30
  • 项目状态:
    已结题

项目摘要

Muscle and bone loss are hallmark consequences of spinal cord injury (SCI) that impede physical rehabilitation and worsen health outcomes. This musculoskeletal decline is precipitated by disuse resulting from the neurologic insult and is intensified by other factors, including impaired insulin-like growth factor (IGF)-1 signaling in muscle and bone. The presence of multifactorial impairments likely underlies the relative ineffectiveness of most stand-alone pharmacologic and mechanical reloading strategies in regenerating both bone and muscle after severe SCI. Our goal is to establish a multimodal strategy combining physical rehabilitation with adjuvant IGF-1 to promote musculoskeletal recovery after SCI, thus addressing both the disuse and the impaired anabolic signaling. Our data indicate that passive Cycle training and bodyweight supported treadmill (TM) training, forms of activity-based physical rehabilitation, reduce muscle loss and promote neuroplasticity in rodents after moderate contusion SCI. However, these physical rehabilitation regimens are relatively ineffective in regenerating muscle and bone after severe SCI. IGF-1 is known to independently influence musculoskeletal integrity, suggesting this anabolic may represent a viable candidate to improve physical rehabilitation after SCI. Indeed, our data indicate that viral overexpression of IGF-1 in muscle protects muscle during disuse and promotes muscle and bone recovery upon reloading. Additionally, viral IGF- 1 expression has been shown to promote corticospinal motor neuron survival after spinal cord transection, an effect essential to the preservation of muscle function after SCI. However, viral IGF-1 therapies are not highly translational. To address this, we developed a novel orally-bioavailable human IGF-1 expressed in edible plants (Plant-Pro-IGF-1) and optimized a dosing regimen in rats and mice that increases circulating IGF-1 by 300-500% for at least 12 h, without suppressing circulating glucose. We have also demonstrated that Plant- Pro-IGF-1 reaches skeletal muscle, the primary target tissue, and that Plant-Pro-IGF-1 phosphorylates IGFR and Akt in time and dose-dependent manners in cultured cells, validating bioactivity. For this proposal, we will evaluate Plant-Pro-IGF-1 alone and in combination with activity-based physical rehabilitation in our rodent severe contusion SCI model, which represents the next step in translating this highly novel compound to clinical trials in the SCI population. All studies will be conducted in 4-month old male and female Sprague- Dawley rats receiving Sham surgery vs severe mid-thoracic (T9) contusion SCI. We will perform experiments using immediate and delayed treatment strategies to determine preventative and regenerative efficacy, respectively, which provides insight into the most appropriate treatment window. We will also assess the influence of passive (Cycle) vs dynamic (TM) loading on IGF-1 efficacy and we will evaluate forelimb and hindlimb musculoskeletal outcomes to determine if therapeutic efficacy requires normal innervation or unimpaired locomotor activity, factors that are only present in forelimbs after severe T9 SCI. Outcomes include: muscle cross sectional area (via MRI), muscle morphology (via immunohistochemistry), isolated muscle mechanics, muscle IGF-1 signaling, bone volume (via microCT), bone turnover (via histomorphometry and circulating markers), soleus corticospinal motor neuron morphology/distribution, and serum IGF-1, IGF binding protein 3, and glucose. This proposal has two Specific Aims: Aim 1. Evaluate the ability of administered IGF-1 to enhance the acute musculoskeletal effects of activity-based physical rehabilitation in a rodent contusion SCI model. Aim 2. Determine if a multimodal therapy combining activity-based physical rehabilitation with adjuvant IGF-1 regenerates bone and muscle when administered chronically after severe SCI.
肌肉和骨丢失是脊髓损伤(SCI)的标志性后果,阻碍了身体康复 并使健康状况恶化。这种肌肉骨骼的衰退是由于 神经损伤,并由其他因素加剧,包括受损的胰岛素样生长因子(IGF)-1 肌肉和骨骼中的信号。多因素损伤的存在可能是相对 大多数独立的药理学和机械重新加载策略在再生两者中的无效性 严重SCI后的骨骼和肌肉。我们的目标是建立一个多模式的战略结合物理 康复与辅助IGF-1,以促进SCI后肌肉骨骼恢复,从而解决这两个问题, 废用和受损的合成代谢信号。我们的数据表明,被动循环训练和体重 支持跑步机(TM)训练,以活动为基础的身体康复形式,减少肌肉损失, 促进啮齿类动物中度挫伤SCI后的神经可塑性。然而,这些物理康复 治疗方案在严重SCI后再生肌肉和骨骼方面相对无效。已知IGF-1 独立地影响肌肉骨骼的完整性,这表明这种合成代谢可能是一个可行的候选人, 改善SCI后的身体康复。事实上,我们的数据表明,肌肉中IGF-1的病毒过表达 在废用过程中保护肌肉,并在重新加载时促进肌肉和骨骼的恢复。此外,病毒IGF- 1的表达已被证明可促进脊髓横断后皮质脊髓运动神经元的存活, 对脊髓损伤后肌肉功能的保护至关重要。然而,病毒IGF-1疗法并不高 翻译为了解决这个问题,我们开发了一种新的口服生物可利用的人IGF-1表达在可食用的 植物(Plant-Pro-IGF-1),并优化了大鼠和小鼠的给药方案, 300-500%至少12小时,不抑制循环葡萄糖。我们还证明了植物- Pro-IGF-1到达骨骼肌,主要靶组织,并且Plant-Pro-IGF-1磷酸化IGFR 和Akt在培养的细胞中以时间和剂量依赖的方式表达,验证生物活性。对于这一建议,我们将 在我们的啮齿动物中评估Plant-Pro-IGF-1单独和与基于活动的身体康复组合 严重挫伤SCI模型,这代表了将这种高度新颖的化合物转化为 SCI患者的临床试验。所有研究将在4个月大的雄性和雌性Sprague中进行。 接受假手术的道利大鼠与严重胸中部(T9)挫伤SCI。我们将进行实验 使用立即和延迟治疗策略来确定预防和再生功效, 这提供了对最合适的治疗窗口的洞察。我们亦会评估 被动(循环)与动态(TM)负荷对IGF-1功效影响,我们将评估前肢和 后肢肌肉骨骼结局,以确定治疗有效性是否需要正常的神经支配或 未受损的运动活动,严重T9 SCI后仅存在于前肢的因素。成果包括: 肌肉横截面积(通过MRI)、肌肉形态学(通过免疫组织化学)、离体肌肉 力学、肌肉IGF-1信号传导、骨体积(通过microCT)、骨转换(通过组织形态计量学和 循环标志物)、比目鱼肌皮质脊髓运动神经元形态/分布和血清IGF-1、IGF结合 蛋白质3和葡萄糖。该提案有两个具体目标: 目标1。评价给予IGF-1增强急性肌肉骨骼效应的能力, 在啮齿动物挫伤SCI模型中进行基于活动的身体康复。 目标二。确定多模式治疗结合基于活动的物理康复与 严重SCI后长期给予辅助性IGF-1可使骨骼和肌肉再生。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Joshua F. Yarrow其他文献

Joshua F. Yarrow的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Joshua F. Yarrow', 18)}}的其他基金

ShEEP Request for High Resolution Desktop MicroCT System
SheEEP 请求高分辨率桌面 MicroCT 系统
  • 批准号:
    10538047
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
Development and Validation of a Rodent FES Bicycle System
啮齿动物 FES 自行车系统的开发和验证
  • 批准号:
    10367994
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
Development and Validation of a Rodent FES Bicycle System
啮齿动物 FES 自行车系统的开发和验证
  • 批准号:
    10554098
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
Locomotor Training with Anabolic Adjuvants for Musculoskeletal Recovery After SCI
使用合成代谢佐剂进行运动训练以促进 SCI 后的肌肉骨骼恢复
  • 批准号:
    10407486
  • 财政年份:
    2018
  • 资助金额:
    --
  • 项目类别:
Locomotor Training with Anabolic Adjuvants for Musculoskeletal Recovery After SCI
使用合成代谢佐剂进行运动训练以促进 SCI 后的肌肉骨骼恢复
  • 批准号:
    10840774
  • 财政年份:
    2018
  • 资助金额:
    --
  • 项目类别:
Role Of Bone Blood Flow In Bone Loss Following SCI
骨血流量在 SCI 后骨质流失中的作用
  • 批准号:
    9236938
  • 财政年份:
    2016
  • 资助金额:
    --
  • 项目类别:
Higher-Than-Replacement Testosterone Plus Finasteride Treatment After SCI
SCI 后高于替代睾酮加非那雄胺的治疗
  • 批准号:
    9901435
  • 财政年份:
    2015
  • 资助金额:
    --
  • 项目类别:
Higher-Than-Replacement Testosterone Plus Finasteride Treatment After SCI
SCI 后高于替代睾酮加非那雄胺的治疗
  • 批准号:
    10251014
  • 财政年份:
    2015
  • 资助金额:
    --
  • 项目类别:
In Vivo Microcomputed Tomography (uCT) Acquisition
体内微计算机断层扫描 (uCT) 采集
  • 批准号:
    8948248
  • 财政年份:
    2015
  • 资助金额:
    --
  • 项目类别:
Higher-Than-Replacement Testosterone Plus Finasteride Treatment After SCI
SCI 后高于替代睾酮加非那雄胺的治疗
  • 批准号:
    10275496
  • 财政年份:
    2015
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了